An agreement signed between British pharmaceutical company AstraZeneca and the biotechnology company mAbxience of the INSUD Group includes transfer of technology to initially produce 150 million doses of the vaccine to supply all of Latin America with the exception of Brazil, the Argentine government said.

"Latin American production will be handled in Argentina and Mexico and that will allow timely and efficient access for all countries in the region," Fernandez said.

Mexican Foreign Minister Marcelo Ebrard said later on Twitter that the deal had been pushed by Fernandez and Mexican President Andres Manuel Lopez Obrador. He said output of the vaccine could extend to 250 million doses.

AstraZeneca, Britain's second-largest drugmaker, has long operations in Argentina. The company signed a deal with the foundation of Mexican billionaire Carlos Slim for production of the vaccine, which is expected to be delivered in the first half of 2021, pending Phase III studies and regulatory approvals.

Mexico would provide more details on the agreement on Thursday, said Ebrard, who thanked the Slim foundation for financing production.

Fernandez said the deal "gives Argentina the peace of mind of being able to have the vaccine when required and at a reasonable price."

Argentina, which has passed 5,000 coronavirus fatalities, posted a record daily number of COVID-19 infections on Wednesday with 7,663 new cases. There were more than 200 fatalities over the previous 24-hour period.

"This will provide great relief in the future, but it is not a solution for the present," added Fernandez, pointing to the growing numbers of infections and fatalities.